November 8, 2026 · Journal of hepatology · DOI: 10.1016/j.jhep.2026.10.021

Seladelpar for alkaline phosphatase normalization in primary biliary cholangitis: The IDEAL phase III randomized controlled trial.

Listen to this summary

Seladelpar, a selective PPAR-delta agonist, was tested in a phase III randomized, double-blind trial to determine whether it can normalize alkaline phosphatase (ALP) in patients with primary biliary cholangitis whose ALP is above normal but below 1.67× the upper limit of normal despite ursodeoxycholic acid (UDCA) therapy or UDCA intolerance. At Month 12, ALP normalization (≤ULN with at least a 15% decrease) occurred in 75.4% of seladelpar-treated patients versus 16.1% on placebo, with similar adverse event rates and fewer serious adverse events. These results suggest seladelpar can achieve biochemical normalization in this lower-threshold group, which may inform treatment goals for patients at higher risk of progression.

Cynthia Levy, Susheela Carroll, Kris V Kowdley, Christopher L Bowlus, Ira M Jacobson, Marlyn J Mayo, Sonal Kumar, Stuart C Gordon, Hin Hin Ko, Mitchell L Shiffman, Ziad Younes, Yan Zhou, Mark Sheng, Anna Zagorska, Daria B Crittenden

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

“

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play